Search Within

Adult Leukemia

  1. "Radiology, Department of"
  2. "Bone Marrow Transplant"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (4)
  3. Conference Paper (1)
Groups
  1. Bone Marrow Transplant (12)
  2. Center for Hematologic Malignancies (12)
  3. Department of Medicine (12)
  4. Hematologic Malignancies, Division of (12)
  5. Radiology, Department of (12)
  6. Molecular Imaging and Therapy Service (10)

More Groups

People
  1. Gunjan Shah (6)
  2. Jae Park (6)
  3. Sean Devlin (6)
  4. Craig Sauter (5)
  5. Michael Scordo (5)
  6. David Scheinberg (4)

More People

Years
  1. 2023 (3)
  2. 2022 (2)
  3. 2021 (2)
  4. 2008 (1)
  5. 2003 (1)
  6. 1996 (1)

More Years

Publications
  1. Blood (5)
  2. Bone Marrow Transplantation (1)
  3. Cancer Research (1)
  4. Experimental Hematology (1)
  5. International Journal of Radiation Oncology, Biology, Physics (1)
  6. Nature Medicine (1)

More Publications

Publishers
  1. American Society of Hematology (5)
  2. Elsevier Inc. (2)
  3. Nature Publishing Group (2)
  4. American Association for Cancer Research (1)
  5. Elsevier Science, Inc. (1)
  6. Massachusetts Medical Society (1)

Results (12)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2
    Meeting Abstract

    Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: Phase 2 trial interim results
    Journal Article

    Park, J. H.; Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G.; Dahi, P.; Lin, R. J.; Scordo, M.; Perales, M. A.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Bridging radiation rapidly and effectively cytoreduces high-risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy
    Journal Article

    Hubbeling, H.; Silverman, E. A.; Michaud, L.; Tomas, A. A.; Shouval, R.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Tringale, K. R.; Batlevi, C.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Patterns of relapse and risk reduction following tumor debulking by bridging radiotherapy prior to chimeric antigen receptor T cell therapy in non-Hodgkin lymphoma
    Meeting Abstract

    Hubbeling, H. G.; Silverman, E. A.; Michaud, L.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Alarcon Tomas, A.; Shouval, R.; Palomba, M. L.; Batlevi, C. L.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Iomab with adoptive cellular therapy (Iomab-ACT): A pilot study of 131-I apamistamab followed by CD19-targeted car T-cell therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Halton, E.; Kane, P.; Senechal, B.; Geoghegan, E. M.; Reddy, V.; Berger, M. S.; Ludwig, D.; Pandit-Taskar, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Sequential administration of bortezomib, liposomal doxorubicin and dexamethasone (BDD) followed by thalidomide and dexamethasone (TD) results in rapid control of untreated high-risk multiple myeloma (MM) and improves depth of response
    Meeting Abstract

    Landau, H.; Hassoun, H.; Cohen, A.; Hoover, E.; Kewalramani, T.; Boruchov, A.; Klimek, V.; Reich, L.; Riedel, E.; Pandit-Taskar, N.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias
    Journal Article

    Burke, J. M. ; Caron, P. C.; Papadopoulos, E. B.; Divgi, C. R.; Sgouros, G.; Panageas, K. S.; Finn, R. D.; Larson, S. M.; O'Reilly, R. J.; Scheinberg, D. A.; more...
    Bone Marrow Transplantation (2003)

    Fulltext@MSK | Save
  • Passive and active specific immunotherapy of myeloid leukemias
    Meeting Abstract

    Scheinberg, D. A.; Bocchia, M.; Jurcic, J.; Caron, P.; Larson, S.; Papadopoulos, E.
    Experimental Hematology (1996)

    Fulltext@MSK | Save